Mazdutide, a dual glucagon and GLP-1 agonist, is approved
A 5-star review of a specific provider doesnt generalize to the next provider
Its clear that it offers immense benefits not only for people with diabetes but also for those without it
Although the sample size was small with only 48 total participants randomized across the two treatment conditions, the randomized, double-blinded, experimental design provides some compelling preliminary evidence that semaglutide might reduce alcohol craving and the amount of alcohol consumed on drinking days in people with alcohol use disorder not actively seeking treatment
Compounded medications are made for individual patients under the supervision of a prescribing physician, allowing the dose and formulation to be tailored to each patients body, tolerance, and weight loss goals
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials